Scarica l'app Stockscreener
5.80
1.22%
0.07
Dopo l'orario di chiusura:
5.80
Precedente Chiudi:
$5.73
Aprire:
$5.72
Volume 24 ore:
535.00K
Relative Volume:
2.22
Capitalizzazione di mercato:
$273.96M
Reddito:
$31.37M
Utile/perdita netta:
$-53.77M
Rapporto P/E:
-3.9898
EPS:
-1.4537
Flusso di cassa netto:
$-49.02M
1 W Prestazione:
-4.61%
1M Prestazione:
-16.67%
6M Prestazione:
+1.22%
1 anno Prestazione:
-13.69%
Intervallo 1D:
$5.55
$6.08
Intervallo di 1 settimana:
$5.55
$6.27
Portata 52W:
$1.97
$7.775
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Nome
Silence Therapeutics Plc Adr
Settore
Industria
Telefono
44-0-20-3457 6900
Indirizzo
12 HAMMERSMITH GROVE, LONDON
Confronta SLN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
5.80 | 270.65M | 31.37M | -53.77M | -49.02M | -1.4537 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Iniziato | Goldman | Sell |
| 2024-12-02 | Reiterato | BMO Capital Markets | Outperform |
| 2024-09-03 | Iniziato | Jefferies | Buy |
| 2024-01-31 | Iniziato | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Borsa (SLN) Ultime notizie
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade - MSN
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Recommendation of “Hold” from Analysts - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Silence Therapeutics appoints CFO Rhonda Hellums to board of directors - Investing.com
Silence Therapeutics CEO Craig Tooman steps down By Investing.com - Investing.com India
Silence Therapeutics CEO Craig Tooman steps down - Investing.com
Frazier Life Sciences Management L.P. Decreases Holdings in Silence Therapeutics PLC Sponsored ADR $SLN - MarketBeat
Does Silence Therapeutics Plc ADR (SLN) offer a good opportunity for investors? - setenews.com
Saturn V Capital Management LP Lowers Position in Silence Therapeutics PLC Sponsored ADR $SLN - MarketBeat
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Silence Therapeutics Plc ADR (SLN) is looking forward to a strong quarter - Setenews
Falcon’s Beyond Global Inc (FBYD) expanding its growth trajectory ahead - setenews.com
Net current asset value per share of Silence Therapeutics PLC Sponsored ADR – FWB:XRP2 - TradingView
HC Wainwright Has Bullish Forecast for SLN FY2025 Earnings - Defense World
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference - Barchart.com
Brokerages Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) PT at $32.60 - Defense World
SLN: Revenue fell, net loss widened, and cash will fund operations into 2028, but more funding needed - TradingView
Silence Therapeutics (SLN) Expected to Announce Quarterly Earnings on Thursday - Defense World
Silence Therapeutics (NASDAQ:SLN) Stock Price Down 2.1%Time to Sell? - MarketBeat
Our approach to nucleotide-based therapeutics - AstraZeneca
5 Under-the-Radar Biotech Stocks That Could Soar in 2026 - Barchart.com
Silence Therapeutics completes enrollment in PV treatment study - Investing.com
Check Out Insider Trades For Silence Therapeutics Plc ADR (SLN) Stock - fostersleader.com
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $32.60 Average Price Target from Analysts - Defense World
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
GAMMA Investing LLC Buys 4,773 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - Defense World
Goldman Sachs Group Inc. Sells 12,510 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $32.60 Consensus Target Price from Analysts - Defense World
Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer - GlobeNewswire Inc.
Silence Therapeutics (OTCMKTS:SLNCF) Shares Down 5% – Here’s What Happened - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Silence Therapeutics (SLN) Stock Price, News & Analysis - MarketBeat
Silence Therapeutics director Michael Davidson resigns from board - Investing.com
Silence Therapeutics director Michael Davidson resigns from board By Investing.com - Investing.com India
William Blair Issues Pessimistic Forecast for SLN Earnings - Defense World
Silence Therapeutics earnings missed by $0.06, revenue fell short of estimates - Investing.com South Africa
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $33.83 Average PT from Analysts - Defense World
Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to Trade - Yahoo.co
Stephens Inc. AR Invests $260,000 in Evergy Inc. (NASDAQ:EVRG) - Defense World
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Price Up 20.7% – Still a Buy? - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus - Nasdaq
Silence Therapeutics soars 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet - Yahoo Finance
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Silence Therapeutics stock hits 52-week low at $3.19 - Investing.com
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know - Nasdaq
Earnings call transcript: Silence Therapeutics sees stock rise post-earnings - Investing.com
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - Nasdaq
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com
Silence Therapeutics stock holds Buy rating on positive trial results By Investing.com - Investing.com UK
Silence Therapeutics Plc Adr Azioni (SLN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):